Applications of Cis-4-Hydroxy-L-Proline in Industrial Manufacturing

We supply Cis-4-Hydroxy-L-Proline to specialized B2B downstream processors across several tightly regulated sectors. As an advanced chiral amino acid, it plays a vital role in technically demanding formulations where both structural and functional performance are critical. Below, we detail its real-world uses by application scenario, referencing practical manufacturing data, regulatory requirements, and industrial processing knowledge.

1. Peptide Synthesis for Pharmaceutical Intermediates

Pharmaceutical peptide manufacturers rely on Cis-4-Hydroxy-L-Proline for assembling bioactive peptides and APIs, particularly when precise stereochemistry is non-negotiable. This amino acid is introduced at the solid-phase peptide synthesis (SPPS) or liquid-phase stage, providing the hydroxyproline residue essential for molecule conformation and biological activity. Its consistent quality and enantiopurity are closely monitored, as these directly affect downstream product performance and regulatory approval outcomes.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• European Pharmacopoeia (Ph. Eur.) monographs for peptide substances
• US FDA CFR Title 21, Part 211 Current Good Manufacturing Practice
• Japanese Pharmacopoeia standards

Typical usage ratio

• 0.5%–5% relative to total amino acid content, adjusted based on target peptide sequence
• Ratio varies by peptide length and hydroxyproline positional requirement

Downstream process integration

• Added during amino acid activation/coupling step in SPPS reactors
• Dissolved in protected form with coupling agents (e.g., HATU, DIC) in peptide chain assembly

Final product types

• Therapeutic peptides (e.g., collagen mimetic peptides)
• API precursors featuring hydroxyproline motifs
• Bioactive research peptides

2. Collagen-Based Biomaterials Manufacturing

Producers of medical-grade collagen hydrogels, scaffolds, and films employ Cis-4-Hydroxy-L-Proline as a collagen precursor during fermentation or chemical synthesis. This ensures controlled incorporation of hydroxyproline into triple-helix domains, improving mechanical properties, bioabsorption rates, and eventual regulatory acceptance for implantable or wound-care applications. Integration procedures focus on lot traceability, raw material purity, and documentation for medical device approval.

Industry compliance standards

• ISO 13485 Quality Management Systems for Medical Devices
• European Union Medical Device Regulation (MDR 2017/745)
• US FDA 21 CFR Part 820 Quality System Regulation
• USP <1044> Biological Reactivity Tests

Typical usage ratio

• 0.25%–2% by weight, depending on the collagens' hydroxyproline content target
• Optimized for required tensile strength and in vivo degradation rates

Downstream process integration

• Supplied to fermentation media for bioengineered collagen synthesis
• Blended in reaction feed before polymerization for semi-synthetic scaffolds

Final product types

• Implantable collagen scaffolds
• Wound-healing dressings
• Artificial skin matrices

3. Chiral Building Block in Agrochemical Synthesis

Chemical manufacturers use Cis-4-Hydroxy-L-Proline as a stereoselective precursor in synthesis routes for advanced agrochemical actives, such as plant growth regulators and certain herbicides. Its unique chiral center is indispensable in generating specific stereoisomers that display superior biological selectivity and reduced environmental impact. Process engineers balance input costs with overall yield and downstream purification requirements to meet agricultural safety standards.

Industry compliance standards

• FAO and WHO Specifications for Plant Protection Products
• REACH Regulation (EC) No. 1907/2006
• ISO 9001:2015 Quality Management Systems

Typical usage ratio

• 1%–10% of total precursor input, determined by the synthetic route and target molecule
• Higher ratios used in routes prioritizing enantiopurity

Downstream process integration

• Charged into batch reactors at initial coupling or cyclization stages
• Subject to subsequent derivatization for side-chain introduction

Final product types

• Chiral agroactive intermediates
• Selective herbicide constituents
• Plant growth modulation agents

4. Functional Ingredient in Clinical Nutrition Formulations

Clinical nutrition product developers formulate special dietary supplements and intravenous nutrition solutions with precisely measured hydroxyproline. The ingredient contributes specifically to supporting connective tissue repair and metabolic balance in patients with increased turnover or special medical needs. Compliance teams emphasize raw material traceability and ingredient testing to meet dietary and parenteral safety regulations.

Industry compliance standards

• Codex Alimentarius Guidelines for Food for Special Medical Purposes
• US FDA 21 CFR Part 104—Nutritional Quality Guidelines
• ISO 22000 Food Safety Management Systems
• EU Regulation (EC) No 609/2013 on Food Intended for Infants and Young Children, Food for Special Medical Purposes, and Total Diet Replacement for Weight Control

Typical usage ratio

• 0.01%–0.2% w/w, variable for oral vs. parenteral nutrition; set to align with patient safety and efficacy data
• Adjusted based on specific formulation type and clinical guidance

Downstream process integration

• Hydrolyzed and sterilized prior to blending into final oral or IV formula
• Incorporated during aqueous solution preparation or spray-drying process

Final product types

• Medical nutrition drinks for recovery care
• Total parenteral nutrition (TPN) solutions
• Oral supplements for tissue regeneration

5. Advanced Cosmetic Peptide Ingredient Production

Cosmetic peptide manufacturers utilize Cis-4-Hydroxy-L-Proline when constructing bioactive tripeptides and oligopeptides for anti-aging and skin-repair applications. It is introduced at specific elongation steps to mimic skin collagen or function as a targeted signaling molecule. Quality oversight focuses on allergen control, traceability, and alignment with international cosmetic ingredient reporting systems.

Industry compliance standards

• ISO 22716 Cosmetics Good Manufacturing Practices (GMP)
• EU Cosmetic Regulation EC 1223/2009
• INCI (International Nomenclature of Cosmetic Ingredients) registration

Typical usage ratio

• 0.1%–1% by mass in peptide formulations, tailored to peptide complexity and bioactivity
• Dosage depends on desired level of peptide biomimicry

Downstream process integration

• Supplied as a resin-bound or protected derivative during peptide chain extension in synthesizers
• Subject to final deprotection and purification alongside other bioactive amino acids

Final product types

• Cosmetic grade bioactive tripeptides
• Collagen-analogous oligopeptides used in skincare
• Peptide-based anti-aging actives